Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)

In a report released yesterday, Shirley Chen from Barclays maintained a Buy rating on AstraZeneca. The company’s shares closed yesterday at p14,026.00.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Chen is a 3-star analyst with an average return of 6.2% and a 58.62% success rate. Chen covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, Novartis AG, and AstraZeneca.

Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of p14,426.48, representing a 2.86% upside. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a £160.00 price target.

Based on AstraZeneca’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of p15.19 billion and a net profit of p2.53 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p1.47 billion

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.